| Autor: |
Honkavaara, J. M., Restitutti, F., Raekallio, M. R., Kuusela, E. K., Vainio, O. M. |
| Předmět: |
|
| Zdroj: |
Journal of Veterinary Pharmacology & Therapeutics; Aug2011, Vol. 34 Issue 4, p332-337, 6p, 1 Chart, 6 Graphs |
| Abstrakt: |
Different doses of MK-467, a peripheral alpha2-adrenergic receptor antagonist, with or without dexmedetomidine were compared in conscious dogs. Eight animals received either dexmedetomidine (10μg / kg [D]), MK-467 (250μg / kg [M250] or dexmedetomidine (10μg / kg) with increasing doses of MK 467 (250μg / kg [DM250], 500μg / kg [DM500] and 750μg / kg [DM750], respectively). Treatments were given intravenously (i.v.) in a randomized, crossover design with a 14-day washout period. Systemic hemodynamics and arterial blood gas analyses were recorded at baseline and at intervals up to 90 min after drugs administration. Dexmedetomidine alone decreased heart rate, cardiac index and tissue oxygen delivery and increased mean arterial pressure and systemic vascular resistance 5 min after administration. DM250 did not completely prevent these early effects, while DM750 induced a decrease in mean arterial pressure. With DM500, systemic hemodynamics remained stable throughout the observational period. MK-467 alone increased cardiac index and tissue oxygen delivery and had no deleterious adverse effects. No differences in arterial blood gases were observed between treatments that included dexmedetomidine. It was concluded that MK-467 attenuated or prevented dexmedetomidine's systemic hemodynamic effects in a dose-dependent manner when given simultaneously i.v. but had no effect on the pulmonary outcome in conscious dogs. A 50:1 dose ratio (MK-467:dexmedetomidine) induced theμeast alterations in cardiovascular function. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text